FDA Approves TEZSPIRE® for Self-Administration in Severe Asthma Patients Aged 12+
Amgen and AstraZeneca announced today that TEZSPIRE® (tezepelumab-ekko) has received approval from the U.S. FDA for self-administration in a pre-filled, single-use pen for severe asthma patients aged ...